basal ganglia disease: A disease involving the basal ganglia.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
724 |
4. Check minimum number of eventsNone |
724 |
5. Include endpointsNone |
724 |
6. Filter based on genotype QC (FinnGen only) |
661 |
Control definitions (FinnGen only)
- Control exclude
- G6_XTRAPYR
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G20-G26
- Name in latin
- Alii morbi degenerativi gangliorum basalium
Similar endpoints
↥List of similar endpoints to
Other degenerative diseases of the basal ganglia
based on the number of shared cases.
Similar with more cases:
- Extrapyramidal and movement disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4228 | 1862 | 2313 |
| Only index persons | 3359 | 1496 | 1863 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.05 | 0.06 |
| Only index persons | 0.06 | 0.05 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 72.48 | 72.52 | 72.47 |
| Only index persons | 72.80 | 72.69 | 72.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 661 | 261 | 400 |
| Unadjusted period prevalence (%) | 0.15 | 0.09 | 0.18 |
| Median age at first event (years) | 73.33 | 72.07 | 74.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 676
- Matched controls
- 6760
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
+∞
307.7
358
*
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
760.9
307.7
518
29
G23.9
ICD-10 Finland
Degenerative disease of basal ganglia, unspecified
+∞
307.7
308
*
G20
ICD-10 Finland
Parkinson disease
+∞
307.7
359
*
N87
ICPC
Parkinsonism
1246.3
265.5
242
*
G23.1
ICD-10 Finland
Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
+∞
248.8
223
*
G23.8
ICD-10 Finland
Other specified degenerative diseases of basal ganglia
+∞
140.7
130
*
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
373.4
124.8
122
*
R25.1
ICD-10 Finland
Tremor, unspecified
16.9
102.5
89
60
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.4
86.1
171
341
L28
ICPC
Limited function/disability (L)
4.6
84.3
316
1076
R4130
NOMESCO Finland
Speech therapy
12.5
82.1
85
77
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
+∞
79.8
75
*
D21
ICPC
Swallowing problem
15.9
77.8
69
48
N04BC05
ATC
pramipexole; oral
6.9
76.0
133
232
N04BD01
ATC
selegiline; oral
210.5
73.8
75
*
N04BC04
ATC
ropinirole; oral
201.0
70.6
72
*
N99
ICPC
Neurological disease other
16.8
69.9
60
39
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
+∞
68.9
65
*
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
10.3
68.8
81
88
N06DA03
ATC
rivastigmine; oral, transdermal
7.0
67.9
115
193
G23.2
ICD-10 Finland
Multiple system atrophy, parkinsonian type [MSA-P]
+∞
62.5
59
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.7
59.0
293
1162
R53
ICD-10 Finland
Malaise and fatigue
3.7
58.6
296
1185
A28
ICPC
Limited function/disability NOS
3.7
58.0
285
1120
N05AH04
ATC
quetiapine; oral
4.2
57.7
194
587
AA1AD
NOMESCO Finland
CT of head and brain
3.5
56.9
374
1761
SPAT1229
SPAT
Assessment of need for aid
4.8
55.1
144
358
N03AE01
ATC
clonazepam; systemic
6.6
52.2
91
156
N04BD02
ATC
rasagiline; oral
+∞
49.6
47
*
SPAT1216
SPAT
Assessment of functional ability
3.5
49.1
235
893
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.8
47.0
119
286
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
9.6
47.0
57
64
N19
ICPC
Speech disorder
12.9
46.6
46
38
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
+∞
46.4
44
*
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
13.0
44.8
44
36
G04BD12
ATC
mirabegron; oral
3.6
44.7
193
682
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
164.2
44.4
46
*
R13
ICD-10 Finland
Dysphagia
4.3
41.2
120
321
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.9
40.1
339
1746
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.4
36.7
158
551
S01.0
ICD-10 Finland
Open wound of scalp
3.9
36.2
123
366
R47.1
ICD-10 Finland
Dysarthria and anarthria
10.3
36.0
41
42
A04
ICPC
Weakness/tiredness general
3.2
35.9
182
700
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.8
35.6
127
391
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.2
35.5
107
292
R5110, ,
SPAT
3.6
35.1
133
426
XA800
NOMESCO Finland
Neuropsychological investigation
6.3
34.6
61
105
N28
ICPC
Limited function/disability (N)
7.6
34.3
50
70
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.0
34.1
198
820
I95.1
ICD-10 Finland
Orthostatic hypotension
4.8
33.7
81
185
G90.3
ICD-10 Finland
Multi-system degeneration
+∞
33.6
32
*
SPAT1231
SPAT
Assessment of adjustments needed in living environment
7.3
33.1
50
73
N06AB10
ATC
escitalopram; oral
3.2
31.8
156
585
G25.0
ICD-10 Finland
Essential tremor
10.2
31.5
36
37
A06AD11
ATC
lactulose; oral
3.0
31.4
182
749
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
8.6
30.6
40
49
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
+∞
30.4
29
*
193
Kela drug reimbursment
Rasagiline
+∞
30.4
29
*
N06AX11
ATC
mirtazapine; oral
2.5
29.2
291
1563
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.9
29.1
171
707
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.7
28.4
98
293
G23.3
ICD-10 Finland
Multiple system atrophy, cerebellar type [MSA-C]
+∞
28.3
27
*
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
5.8
28.2
53
97
TAB00
NOMESCO Finland
Lumbar puncture
4.9
27.7
64
141
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.4
27.5
286
1558
N04BC09
ATC
rotigotine; transdermal
281.7
26.9
27
*
G31.8
ICD-10 Finland
Other specified degenerative diseases of nervous system
24.4
26.4
37
16
H02AA02
ATC
fludrocortisone; oral
22.9
25.9
37
17
JDB10
NOMESCO Finland
Percutaneous gastrostomy
8.8
25.1
32
38
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.0
25.0
76
207
N29
ICPC
Neurological sympt/complt other
7.1
24.9
38
56
SPAT1234
SPAT
Support of social functional capacity
4.0
24.7
76
209
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.6
24.6
178
811
N04BX02
ATC
entacapone; oral
+∞
24.1
23
*
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
4.0
23.7
72
196
N04BB01
ATC
amantadine; oral
9.7
23.7
28
30
N04AA02
ATC
biperiden; systemic
9.1
22.6
28
32
R4120, ,
SPAT
7.9
22.2
31
41
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.5
22.2
81
250
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.5
22.1
57
137
R42
ICD-10 Finland
Dizziness and giddiness
2.3
21.0
225
1214
M03BX01
ATC
baclofen; systemic
6.6
20.7
34
54
N02AA05
ATC
oxycodone; systemic
2.3
20.3
211
1120
N05BA04
ATC
oxazepam; oral
2.3
20.2
216
1160
N03AG01
ATC
valproic acid; systemic, rectal
3.9
19.9
61
167
U04
ICPC
Incontinence urine
3.2
19.5
83
282
XF606
NOMESCO Finland
Ortostatic test
16.2
19.4
31
20
N30.0
ICD-10 Finland
Acute cystitis
2.5
18.7
141
647
SPAT1245
SPAT
Provision of support and information to patient’s family members
3.5
18.6
67
205
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
18.3
260
1551
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.2
17.9
49
123
SPAT1254
SPAT
Administration of medicine
2.4
17.8
148
710
R4130, ,
SPAT
43.2
17.4
21
5
SPAT1294
SPAT
Other function in accordance with health social work nomenclature
4.9
17.3
39
84
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.2
17.2
71
236
P20
ICPC
Memory disturbance
2.2
17.2
174
906
N04BX04
ATC
opicapone; oral
+∞
16.7
16
*
C07AA05
ATC
propranolol; systemic
2.4
16.4
135
642
R4110
NOMESCO Finland
Physiotherapy
2.0
16.2
238
1424
UDQ42
NOMESCO Finland
Endoscopic assessment of swallowing function
34.3
15.8
20
6
N05AH03
ATC
olanzapine; systemic
3.7
15.3
50
143
S01.1
ICD-10 Finland
Open wound of eyelid and periocular area
4.2
15.3
42
106
N06AX16
ATC
venlafaxine; oral
2.5
14.6
101
443
W19
ICD-10 Finland
Unspecified fall
2.5
14.2
96
416
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.2
14.1
57
187
R1250
NOMESCO Finland
Evaluation of functional capability
4.6
13.9
33
74
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.2
13.4
54
177
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.2
13.3
125
625
N06AB04
ATC
citalopram; systemic
2.1
13.3
155
845
SPAT1305
SPAT
Counselling and guidance related to physical exercise
2.5
13.1
91
399
K59.09
ICD-10 Finland
Constipation, unspecified
2.6
12.5
77
318
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.4
12.3
89
398
G91.2
ICD-10 Finland
Normal-pressure hydrocephalus
4.9
12.2
27
57
R32
ICD-10 Finland
Unspecified urinary incontinence
4.0
12.1
35
92
S06.0
ICD-10 Finland
Concussion
2.3
11.9
96
449
R1250, ,
SPAT
3.6
11.7
39
113
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
2.5
11.6
76
324
AA5DR
NOMESCO Finland
Brain metabolism PET with CT
+∞
11.5
11
*
S01.8
ICD-10 Finland
Open wound of other parts of head
4.9
11.0
24
50
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.6
11.0
69
288
R33
ICD-10 Finland
Retention of urine
2.2
10.9
100
493
IGY02
NOMESCO Finland
Psychiatric monitoring contact
5.3
10.8
22
43
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
4.8
10.8
24
51
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.0
10.8
50
178
G21.1
ICD-10 Finland
Other drug-induced secondary parkinsonism
61.0
10.7
12
*
SPAT1301
SPAT
No procedures
1.8
10.6
246
1659
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
8.7
10.6
22
26
Z3226
NOMESCO Finland
Physiotherapist
1.9
10.6
146
839
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
5.5
10.5
20
37
N06AX26
ATC
vortioxetine; oral
3.0
10.1
46
162
G81.9
ICD-10 Finland
Hemiplegia, unspecified
8.6
10.1
21
25
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.4
10.1
71
313
L89
ICD-10 Finland
Decubitus ulcer and pressure area
4.2
10.0
27
67
NA1AD
NOMESCO Finland
Cervical spine CT examination
2.8
9.9
51
192
G25.2
ICD-10 Finland
Other specified forms of tremor
20.4
9.8
14
7
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.9
9.6
129
733
D12
ICPC
Constipation
2.9
9.5
44
157
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.0
9.4
109
588
TKC20
NOMESCO Finland
Catheterisation of bladder
2.3
9.3
73
338
G31.9
ICD-10 Finland
Degenerative disease of nervous system, unspecified
13.9
9.2
15
11
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.1
9.2
89
449
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
5.1
9.1
19
38
Z51.5
ICD-10 Finland
Palliative care
2.0
9.1
101
535
M48.0
ICD-10 Finland
Spinal stenosis
1.9
9.0
120
678
R1260
NOMESCO Finland
Evaluation of communicative skills
4.0
8.9
25
64
R41.3
ICD-10 Finland
Other amnesia
3.1
8.9
38
129
S22.3
ICD-10 Finland
Fracture of rib
2.3
8.9
69
317
R49.08
ICD-10 Finland
Other specified dysphonia
4.0
8.8
25
65
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
1.9
8.7
120
685
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
2.7
8.5
45
172
N05BA06
ATC
lorazepam; systemic, sublingual
2.5
8.5
52
214
S01.41
ICD-10 Finland
Open wound in the temple-jaw region
6.8
8.4
20
30
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
3.8
8.4
25
67
K90
ICPC
Stroke/cerebrovascular accident
2.9
8.4
40
145
G21.8
ICD-10 Finland
Other secondary parkinsonism
+∞
8.3
8
*
G23.0
ICD-10 Finland
Hallervorden-Spatz disease
+∞
8.3
8
*
G24.9
ICD-10 Finland
Dystonia, unspecified
+∞
8.3
8
*
T08
ICPC
Weight loss
4.0
8.2
23
59
N06AX21
ATC
duloxetine; oral
2.1
8.2
78
390
TJD20
NOMESCO Finland
Change of gastrostomy tube
11.9
8.1
14
12
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.6
8.0
307
2316
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
4.7
7.9
18
39
N05AX08
ATC
risperidone; systemic
2.1
7.8
73
362
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
1.9
7.8
105
594
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
4.3
7.8
20
48
N18
ICPC
Paralysis/weakness
3.5
7.7
26
76
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
3.4
7.7
27
81
S01.2
ICD-10 Finland
Open wound of nose
4.6
7.7
18
40
U07.1
ICD-10 Finland
Emergency use of U07.1 | COVID-19, virus identified
1.9
7.6
102
576
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
3.4
7.6
27
82
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
3.3
7.5
27
83
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
6.1
7.4
19
32
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
6.1
7.4
19
32
R5130, ,
SPAT
13.5
7.4
12
9
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
1.6
7.4
212
1486
G31.0
ICD-10 Finland
Circumscribed brain atrophy
8.5
7.3
15
18
R35
ICD-10 Finland
Polyuria
2.1
7.3
67
330
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
+∞
7.3
7
*
G04CB01
ATC
finasteride; oral
1.8
7.3
124
755
SPAT1240
SPAT
Therapeutic discussion
2.4
7.2
51
225
AA400
NOMESCO Finland
Electroconvulsive therapy
12.2
7.1
12
10
XKD00
NOMESCO Finland
Uroflowmetry
1.7
7.1
162
1071
N17
ICPC
Vertigo/dizziness
1.8
7.1
108
636
Z02.7
ICD-10 Finland
Issue of medical certificate
2.2
7.1
59
280
R23
ICPC
Voice symptom/complaint
3.5
6.9
23
67
NE1AA
NOMESCO Finland
Pelvis X-ray examination
2.0
6.9
74
388
F03
ICD-10 Finland
Unspecified dementia
2.5
6.9
44
186
N05AH02
ATC
clozapine; systemic
8.4
6.8
14
17
SPAT1139
SPAT
Nutrition survey
2.8
6.8
34
127
K11.72
ICD-10 Finland
Xerostomia
40.5
6.8
8
*
S72.0
ICD-10 Finland
Fracture of neck of femur
2.5
6.7
42
175
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.0
6.7
77
412
N03AX09
ATC
lamotrigine; oral
3.1
6.7
28
94
R4120
NOMESCO Finland
Occupational therapy
2.3
6.7
52
239
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
1.7
6.7
141
910
J01EA01
ATC
trimethoprim; systemic
1.6
6.7
166
1118
UKC02
NOMESCO Finland
Cystoscopy
1.7
6.7
150
986
H50.52
ICD-10 Finland
Exophoria
5.6
6.6
18
33
U07
ICPC
Urine symptom/complaint other
2.0
6.6
72
378
Z2445
NOMESCO Finland
Psychologist
3.3
6.6
24
74
N03AX14
ATC
levetiracetam; systemic
3.0
6.6
28
95
Z02.4
ICD-10 Finland
Examination for driving licence
0.6
6.6
139
2035
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
1.7
6.6
123
768
SPAT1101
SPAT
Orthostatic test
2.4
6.5
43
184
WW200, ,
SPAT
0.6
6.5
103
1625
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
3.2
6.5
25
80
Z50.5
ICD-10 Finland
Speech therapy
5.8
6.5
17
30
SPAT1167
SPAT
Insertion of urinary catheter
2.6
6.5
37
148
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
70.5
6.4
7
*
SPAT1281
SPAT
Other administrative function
2.1
6.4
62
312
W10
ICD-10 Finland
Fall on and from stairs and steps
2.4
6.4
44
192
J01MA02
ATC
ciprofloxacin; systemic
1.5
6.4
285
2195
Z43.5
ICD-10 Finland
Attention to cystostomy
8.3
6.4
13
16
R27.0
ICD-10 Finland
Ataxia, unspecified
8.3
6.4
13
16
SPAT1053
SPAT
Memory test
1.7
6.3
143
940
SPAT1042
SPAT
Guidance concerning balance maintenance
9.4
6.3
12
13
S00.0
ICD-10 Finland
Superficial injury of scalp
3.1
6.3
26
87
SPAT1262
SPAT
Handing over of treatment supplies
1.7
6.3
139
909
N02BE01
ATC
paracetamol; systemic, rectal
1.9
6.3
606
5537
N04BC02
ATC
pergolide; oral
+∞
6.3
6
*
Z91.5
ICD-10 Finland
Personal history of self-harm
26.9
6.2
8
*
K91
ICPC
Cerebrovascular disease
3.7
6.2
19
52
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
5.8
6.2
16
28
IGY99
NOMESCO Finland
Other psychiatric treatment contact
7.8
6.1
13
17
F80.1
ICD-10 Finland
Expressive language disorder
8.7
6.1
12
14
R63.4
ICD-10 Finland
Abnormal weight loss
2.5
6.1
38
159
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
3.5
6.0
20
58
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
2.8
6.0
29
106
N05AX12
ATC
aripiprazole; systemic
3.9
6.0
17
44
130
Kela drug reimbursment
Malignant tumour
0.3
6.0
16
507
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
47
61
8.21
34.41
1.0
1.0
29.37
44.12
ng/l
1.93
29
38
47
61
8.21
34.41
1.0
1.0
217.87
336.18
ng/l
2.29
32
39
375
2157
2.66
33.96
2.7
2.3
228.16
260.20
u/l
0.27
359
2042
70
141
5.42
33.64
1.3
1.3
2.18
71.29
e6/l
0.93
50
107
70
143
5.35
33.11
1.3
1.4
266.39
1043.42
e6/l
0.47
51
113
46
61
8.02
33.07
1.0
1.0
642.10
580.95
ng/l
0.35
29
38
220
1029
2.69
29.54
2.3
1.9
—
—
—
0
0
259
1343
2.51
27.78
2.3
2.0
—
—
—
0
0
201
962
2.55
25.18
2.4
2.0
—
—
—
0
0
226
1255
2.20
19.36
3.8
3.2
1.73
0.90
e6/l
0.65
128
714
30
45
6.93
19.27
1.0
1.2
—
9.73
nmol/l
—
0
7
441
3218
2.07
17.49
6.2
7.2
1.21
1.21
mmol/l
0.92
412
2951
431
3122
2.05
17.41
5.1
5.6
34.67
34.73
g/l
0.08
408
2935
229
1327
2.10
17.22
1.7
1.8
1151.74
1192.39
nmol/l
0.23
184
1000
430
3129
2.03
16.93
2.6
2.3
90.14
94.45
pmol/l
1.49
262
1667
309
2015
1.98
16.58
4.1
3.6
0.46
0.50
e6/l
0.17
236
1532
117
527
2.48
16.03
2.2
1.7
—
—
—
0
0
29
51
5.90
15.98
1.1
1.1
—
—
—
0
0
464
3518
2.02
15.65
6.8
8.1
1.22
1.21
mmol/l
2.18
411
3009
325
2189
1.93
15.56
2.0
1.8
18.15
19.82
nmol/l
1.39
299
1825
338
2322
1.91
15.09
4.2
3.7
46.14
92.90
e6/l
0.89
261
1831
23
36
6.58
14.18
1.2
1.0
—
—
—
0
0
30
63
4.94
13.66
1.1
1.1
—
—
—
0
0
355
2544
1.83
13.27
5.0
4.3
185.29
123.51
e6/l
0.37
261
1881
34
82
4.31
13.10
5.2
5.0
374.66
357.05
umol/l
0.33
29
73
195
1163
1.95
12.92
4.1
3.4
2.37
1.59
e6/l
0.68
99
621
377
2797
1.79
12.13
3.1
2.4
—
—
—
0
0
427
3292
1.81
12.01
4.9
4.3
0.00
4.64
estimate
0.80
74
755
20
35
5.86
11.06
1.2
1.2
0.48
0.49
ratio
0.09
11
19
331
2418
1.72
10.78
2.5
3.8
2.35
2.35
mmol/l
0.10
300
2185
229
1509
1.78
10.74
2.8
3.3
2.45
2.46
mmol/l
1.01
210
1365
416
3250
1.73
10.49
4.9
4.3
0.00
0.00
estimate
-0.00
66
737
194
1226
1.82
10.42
2.2
3.4
0.82
0.81
mmol/l
0.33
181
1162
422
3317
1.72
10.34
4.9
4.3
0.00
0.44
estimate
0.52
71
702
516
4362
1.77
9.02
4.1
4.1
15.42
15.07
pmol/l
2.30
472
3908
358
2763
1.63
8.79
2.2
2.4
80.44
79.44
nmol/l
0.26
313
2428
171
2503
0.58
8.75
1.8
2.0
1.22
1.28
mmol/l
0.65
154
2007
76
371
2.18
8.48
1.5
1.5
—
—
—
0
0
202
1364
1.69
8.31
4.4
4.4
72.43
345.32
ng/l
4.41
175
1187
236
1660
1.65
8.29
2.7
2.8
4.98
4.29
e6/l
0.46
214
1530
526
4532
1.72
7.87
4.2
4.6
13.18
14.37
mm/h
0.89
486
4193
471
3968
1.62
7.44
5.9
5.6
6.54
6.82
mmol/l
2.89
455
3813
59
287
2.16
6.65
2.0
2.2
519.92
557.35
ug/l
0.04
52
274
232
1698
1.56
6.60
3.8
4.5
82.65
84.84
%
0.68
226
1667
206
1490
1.55
6.09
1.7
1.8
437.78
34044733.65
pmol/l
1.66
174
1219
614
5657
1.93
5.84
26.5
20.1
32.64
27.42
mg/l
3.29
568
4815
422
3561
1.49
5.81
8.3
10.0
4.47
4.25
e9/l
0.98
343
3085
40
176
2.35
5.74
4.7
3.4
1.88
1.92
index
0.01
17
95
197
1427
1.54
5.74
5.5
4.5
1.02
1.02
kg/l
0.63
121
993
540
4815
1.60
5.66
7.2
9.3
78.01
82.70
u/l
1.98
520
4543
51
252
2.11
5.55
1.2
1.3
—
—
—
0
0
579
5262
1.70
5.52
5.6
5.3
1.87
2.07
mu/l
2.00
535
4751
20
64
3.19
5.23
4.6
3.3
7.50
11.69
index
—
8
39
140
967
1.56
4.97
6.6
7.9
1.60
0.91
mmol/l
1.16
127
802
111
727
1.63
4.92
2.0
2.4
0.20
0.20
g/l
0.20
101
674
495
4394
1.47
4.68
34.7
26.6
331.44
331.34
g/l
0.09
489
4370
165
1200
1.50
4.59
1.3
1.2
1.76
1.35
u/ml
0.15
32
308
107
707
1.61
4.57
2.3
3.3
65.43
65.87
g/l
0.28
98
650
12
24
5.07
4.33
1.4
1.2
—
—
—
0
0
97
635
1.62
4.30
3.3
3.3
128.27
222.63
ng/l
4.07
89
582
86
551
1.64
4.16
1.8
1.7
—
—
—
0
0
13
32
4.12
3.92
1.3
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
13
33
4.00
3.81
1.2
1.1
—
—
—
0
0
178
1360
1.42
3.76
1.4
1.7
1.51
1.53
mg/l
0.01
140
1079
235
1895
1.37
3.57
2.5
2.3
2.74
2.99
mg/l
1.04
197
1637
235
1915
1.35
3.29
5.5
4.3
0.00
0.01
estimate
0.78
69
660
623
5928
1.65
3.10
31.9
24.9
139.67
139.62
mmol/l
0.20
614
5814
623
5935
1.63
3.00
32.1
25.1
3.95
4.02
mmol/l
8.43
613
5813
78
529
1.54
3.00
7.3
10.2
0.67
0.65
%
0.16
78
524
13
46
2.86
2.93
3.2
2.4
—
—
—
0
0
109
798
1.44
2.88
9.2
8.6
—
—
—
0
0
286
2434
1.30
2.86
5.3
4.4
0.02
0.03
estimate
0.21
54
615
57
363
1.62
2.86
2.2
1.9
1.03
3.30
ug/l
1.02
44
325
88
619
1.48
2.85
2.0
2.6
33.81
35.20
u/l
0.17
79
512
404
3603
1.30
2.82
3.7
3.5
48.72
58.74
u/l
1.30
369
3333
396
3532
1.29
2.72
5.3
7.4
11.92
12.39
umol/l
0.32
369
3384
314
2720
1.29
2.70
5.0
4.5
39.57
54.81
ng/l
0.59
270
2213
79
550
1.49
2.70
7.4
10.1
93.63
93.86
%
0.12
79
545
27
140
1.97
2.69
1.3
1.3
—
—
—
0
0
27
140
1.97
2.69
1.3
1.3
—
—
—
0
0
79
551
1.49
2.68
7.3
9.8
1.29
1.30
%
0.06
79
545
313
2719
1.28
2.61
2.8
3.1
158.26
158.82
ug/l
0.01
287
2500
93
676
1.44
2.56
2.1
2.7
8.53
7.11
ug/l
0.28
77
607
343
3019
1.28
2.55
2.9
3.1
—
—
estimate
—
0
0
151
1192
1.34
2.54
1.7
2.0
29.59
29.73
s
0.12
145
1156
81
576
1.46
2.50
2.4
4.2
84.43
95.20
ng/l
0.38
68
502
7
17
4.15
2.36
1.0
1.1
—
—
—
0
0
249
2123
1.27
2.35
3.1
2.7
53.65
100.59
u/l
0.67
223
1971
85
622
1.42
2.27
2.2
2.2
405.45
391.35
nmol/l
0.30
75
578
7
18
3.92
2.25
1.1
1.1
—
—
—
0
0
101
763
1.38
2.24
2.5
3.0
7.19
8.99
umol/l
0.82
90
687
46
299
1.58
2.17
2.8
2.8
0.89
1.75
g/l
0.95
40
261
623
5993
1.50
2.17
32.5
27.3
76.96
85.27
umol/l
8.43
615
5917
7
19
3.71
2.15
1.1
1.1
—
—
—
0
0
7
19
3.71
2.15
1.1
1.1
—
—
—
0
0
7
19
3.71
2.15
1.1
1.1
—
—
—
0
0
6
14
4.31
2.15
2.0
2.6
—
—
—
0
0
43
277
1.59
2.11
3.3
4.3
25.58
25.05
mmol/l
0.76
38
257
28
161
1.77
2.09
1.1
1.2
—
—
—
0
0
5
10
5.03
2.07
1.2
1.0
—
—
—
0
0
7
20
3.53
2.06
1.1
1.1
—
—
—
0
0
28
162
1.76
2.05
1.1
1.2
—
—
—
0
0
6
15
4.03
2.04
2.0
2.5
—
—
—
0
0
34
209
1.66
2.02
1.6
1.5
194.32
263.97
ug/g
1.27
19
131
8
26
3.10
2.02
1.4
1.1
—
—
—
0
0
72
523
1.42
2.02
1.4
1.7
1.53
1.70
%
1.53
57
431
33
202
1.67
1.99
1.2
1.4
—
—
—
0
0
33
207
1.62
1.83
1.2
1.3
—
—
—
0
0
100
781
1.33
1.81
3.8
3.7
2.37
1.88
mmol/l
0.58
93
671
155
1287
1.27
1.77
2.5
2.8
11.09
12.33
umol/l
1.33
143
1208
195
1663
1.24
1.77
2.3
2.7
—
—
—
0
0
146
1204
1.27
1.77
2.5
2.8
2.10
2.24
g/l
2.03
134
1127
623
6032
1.42
1.67
37.8
30.4
91.76
91.89
fl
0.29
616
5950
623
6032
1.42
1.67
37.9
30.5
239.94
237.75
e9/l
0.35
609
5891
623
6033
1.42
1.66
38.7
31.1
39.02
39.76
%
3.84
616
5945
623
6033
1.42
1.66
37.9
30.4
4.31
4.41
e12/l
4.96
607
5862
67
499
1.38
1.66
8.2
10.1
24.76
24.29
mmol/l
0.49
67
491
623
6034
1.41
1.65
38.2
30.7
129.31
133.15
g/l
8.70
616
5949
66
867
0.74
1.59
4.2
5.3
33.26
32.27
%
0.37
47
547
221
2507
0.82
1.58
3.4
4.3
6.65
9.73
mg/mmol
0.81
152
1599
137
1137
1.26
1.57
2.6
2.8
20.76
22.21
%
0.62
126
1070
7
27
2.61
1.52
1.1
1.1
—
—
—
0
0
269
2403
1.20
1.50
4.6
5.1
21.41
21.56
%
0.06
136
1308
21
125
1.70
1.45
1.3
1.6
4.60
5.19
iu/l
—
8
46
7
153
0.45
1.44
3.4
5.7
—
356.71
—
0
24
6
22
2.74
1.43
1.5
1.8
58.67
73.48
ug/l
—
6
22
48
347
1.41
1.43
3.1
4.3
1.02
1.02
ratio
1.32
38
326
218
2458
0.83
1.43
3.0
3.5
7.82
7.42
mmol/l
0.65
183
2034
38
265
1.46
1.37
1.8
1.8
—
—
—
0
0
6
23
2.62
1.37
1.2
1.1
—
—
—
0
0
59
448
1.35
1.33
3.1
3.9
2.55
2.14
mmol/l
0.35
39
340
124
1038
1.24
1.33
3.9
6.0
1.00
1.03
mmol/l
0.57
119
965
15
84
1.80
1.28
2.3
3.0
—
—
—
0
0
40
287
1.42
1.26
1.8
2.0
—
—
—
0
0
323
2967
1.17
1.24
5.0
6.4
4.06
3.10
ug/l
0.25
289
2646
40
290
1.40
1.20
2.5
3.9
1.06
1.37
mmol/l
1.52
40
282
67
528
1.30
1.19
3.4
4.0
5.28
5.17
kpa
0.60
62
506
6
26
2.32
1.19
1.0
1.1
—
—
—
0
0
8
38
2.12
1.18
1.1
1.2
—
—
—
0
0
53
405
1.33
1.17
1.3
2.0
1.47
1.51
g/l
0.15
45
364
0
35
0.00
1.15
0.0
1.1
—
—
—
0
0
70
862
0.79
1.08
2.7
4.5
3.11
30.21
ug/l
2.07
50
727
38
280
1.38
1.06
2.2
3.4
4.41
4.36
pmol/l
0.14
33
245
12
67
1.81
1.05
1.1
1.3
—
—
—
0
0
5
22
2.28
1.03
3.8
3.8
9.72
9.45
kpa
—
5
22
5
22
2.28
1.03
3.8
3.8
7.06
4.88
kpa
—
5
22
18
114
1.59
1.03
1.2
1.4
—
—
—
0
0
7
34
2.07
1.03
2.3
3.5
77.43
129.06
nmol/l
—
7
34
367
3440
1.15
1.00
17.8
19.3
1.30
1.33
inr
0.45
308
2909
7
35
2.01
1.00
1.7
1.7
—
—
—
0
0
0
30
0.00
0.97
0.0
2.0
—
—
—
0
0
0
30
0.00
0.97
0.0
2.0
—
—
—
0
0
9
50
1.81
0.97
1.1
1.3
—
—
—
0
0
9
50
1.81
0.97
1.1
1.3
—
—
—
0
0
0
31
0.00
0.96
0.0
2.0
—
—
—
0
0
13
77
1.70
0.95
1.5
1.4
—
—
—
0
0
13
78
1.68
0.92
1.2
1.3
214.50
267.28
pmol/l
—
6
67
224
2042
1.15
0.90
3.2
3.4
33.54
34.27
u/l
0.06
211
1921
12
71
1.70
0.89
1.4
1.2
7860.00
197508.32
e6/l
—
6
47
13
80
1.64
0.85
1.2
1.3
0.65
0.61
nmol/l
0.17
13
75
6
114
0.52
0.83
1.0
1.1
—
—
—
0
0
539
5547
0.86
0.83
4.5
5.6
1.41
1.43
mmol/l
0.62
492
5034
16
236
0.67
0.82
2.0
3.4
144.63
135.67
u/ml
0.02
16
228
23
164
1.42
0.81
1.6
1.5
—
—
—
0
0
0
25
0.00
0.79
0.0
1.1
—
306.67
—
0
15
14
90
1.57
0.78
1.1
1.5
—
—
—
0
0
14
90
1.57
0.78
1.1
1.5
—
—
—
0
0
0
27
0.00
0.77
0.0
1.2
—
—
—
0
0
14
91
1.55
0.75
1.1
1.5
—
—
—
0
0
193
1763
1.13
0.75
3.1
3.6
0.61
0.80
ug/l
2.60
149
1260
544
5585
0.87
0.75
4.7
5.7
4.27
4.40
mmol/l
2.05
499
5116
5
24
2.09
0.74
1.4
1.0
2313.00
1421.00
miu/ml
—
5
24
14
92
1.53
0.72
1.1
1.5
—
—
—
0
0
66
556
1.21
0.72
1.8
2.3
12.48
12.77
nmol/l
0.10
58
479
9
57
1.59
0.71
1.1
1.4
—
—
—
0
0
14
93
1.52
0.70
3.1
4.1
—
—
—
0
0
14
94
1.50
0.67
1.1
1.5
—
—
—
0
0
14
94
1.50
0.67
1.1
1.5
—
—
—
0
0
5
28
1.79
0.66
2.0
2.0
—
—
—
0
0
12
175
0.68
0.61
1.6
1.3
—
—
—
0
0
184
1701
1.11
0.58
4.6
3.8
0.00
0.07
estimate
0.80
56
568
564
5520
1.13
0.56
23.6
20.0
78.42
73.30
ml/min/173m2
9.16
530
5169
86
763
1.15
0.54
5.4
3.8
—
—
—
0
0
6
39
1.54
0.53
1.5
1.3
—
—
—
0
0
14
192
0.72
0.52
1.5
1.5
0.15
0.10
iu/ml
—
5
30
522
5340
0.90
0.52
4.0
4.7
1.20
1.27
mmol/l
1.71
473
4807
10
145
0.68
0.51
1.7
1.9
—
—
—
0
0
602
5926
1.14
0.49
12.4
13.9
22.00
25.19
u/l
4.03
584
5723
7
110
0.63
0.48
1.1
1.1
—
—
—
0
0
8
119
0.67
0.46
2.4
2.8
—
807.20
—
0
10
40
469
0.84
0.45
1.5
1.4
—
—
—
0
0
7
51
1.38
0.44
1.4
1.2
—
—
—
0
0
263
2509
1.08
0.42
2.8
3.4
886.90
1549.75
ng/l
4.94
237
2215
27
222
1.23
0.41
1.1
1.0
—
—
—
0
0
5
33
1.52
0.41
1.8
1.4
432.40
282.58
mu/l
—
5
24
0
15
0.00
0.41
0.0
1.1
—
29.16
—
0
8
0
15
0.00
0.41
0.0
1.9
—
2.37
—
0
6
0
17
0.00
0.40
0.0
2.1
—
2.46
—
0
17
53
600
0.87
0.39
1.3
1.3
—
—
—
0
0
7
104
0.67
0.39
2.0
1.7
—
—
—
0
0
9
68
1.33
0.37
1.4
1.4
—
—
—
0
0
5
78
0.64
0.36
1.0
2.1
—
—
—
0
0
47
414
1.15
0.35
4.4
4.0
54.72
48.11
%
1.12
47
407
9
123
0.73
0.35
1.6
1.4
0.78
0.87
nmol/l
—
9
100
16
126
1.28
0.35
1.6
1.3
—
—
—
0
0
20
244
0.81
0.35
1.3
1.8
10.24
8.35
iu/ml
—
5
64
6
43
1.40
0.35
2.2
2.5
51.67
41.13
mg/l
—
6
30
19
154
1.24
0.34
1.9
1.6
—
—
—
0
0
6
47
1.28
0.32
1.2
1.8
—
—
—
0
0
7
52
1.35
0.31
1.1
1.1
—
—
—
0
0
7
98
0.71
0.31
1.0
1.3
—
—
—
0
0
7
54
1.30
0.30
1.0
1.2
80.43
99.96
pmol/l
—
7
54
173
1810
0.94
0.27
2.5
3.1
341.39
362.73
umol/l
1.81
147
1556
16
193
0.82
0.27
1.4
1.5
—
—
—
0
0
6
83
0.72
0.24
1.0
2.1
—
—
—
0
0
21
180
1.17
0.24
1.9
1.5
—
—
—
0
0
564
5700
0.94
0.23
5.7
6.6
2.40
2.52
mmol/l
2.57
516
5189
32
285
1.13
0.23
1.0
1.2
84.97
125.21
u/ml
0.51
12
100
5
39
1.28
0.23
1.6
1.3
—
—
—
0
0
49
534
0.91
0.22
1.6
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
1.15
—
0
10
12
98
1.23
0.21
1.4
2.3
12.25
11.00
mmol/l
0.50
12
98
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
26
293
0.88
0.21
2.3
2.5
0.33
0.36
iu/ml
0.22
15
161
18
157
1.15
0.17
1.7
1.5
—
—
—
0
0
16
184
0.87
0.17
2.7
2.6
37.34
101.06
ug/min
—
10
105
5
69
0.72
0.17
1.2
1.1
1.87
1.70
nmol/l
—
5
62
8
72
1.11
0.16
1.5
1.3
40.50
29.43
iu/l
—
8
58
15
171
0.87
0.15
1.1
1.2
—
2.59
—
0
7
101
970
1.05
0.14
3.0
4.4
216.44
248.23
u/l
3.67
94
925
48
511
0.93
0.14
2.8
3.1
62.53
58.88
ml/min/173m2
0.19
15
225
8
96
0.83
0.14
1.0
1.4
—
161.28
—
0
26
37
344
1.08
0.13
1.3
1.2
121.66
233.82
u/ml
1.10
32
311
9
108
0.83
0.13
1.8
1.7
—
—
—
0
0
548
5517
0.96
0.12
6.8
7.6
39.04
40.30
mmol/mol
3.39
500
5099
17
153
1.11
0.11
1.1
1.3
—
—
—
0
0
15
134
1.12
0.11
1.7
2.1
1.38
1.60
mmol/l
0.76
15
128
21
229
0.91
0.11
1.9
1.7
—
—
—
0
0
6
57
1.05
0.08
1.5
1.7
—
—
—
0
0
6
70
0.86
0.07
1.0
1.4
12.50
13.13
u/l
—
6
63
6
73
0.82
0.07
1.3
1.7
—
—
—
0
0
6
73
0.82
0.07
1.3
1.7
—
—
—
0
0
6
73
0.82
0.07
1.3
1.7
—
—
—
0
0
6
75
0.80
0.07
1.5
2.8
460.17
1130.56
mg
—
6
75
8
75
1.07
0.07
1.4
1.8
—
—
—
0
0
9
100
0.90
0.06
1.1
1.4
269.44
319.51
u/l
—
9
95
60
582
1.03
0.06
3.7
4.0
1.23
1.22
mmol/l
0.62
49
508
16
172
0.93
0.06
2.9
3.1
15.63
15.85
%
0.14
16
166
19
202
0.94
0.05
2.8
3.1
8.34
7.75
kpa
1.07
19
196
12
110
1.09
0.05
1.8
1.9
5.29
4.68
mmol/24h
0.34
12
95
91
925
0.98
0.04
1.3
1.3
14.98
12.78
u/ml
0.08
33
334
18
190
0.95
0.04
1.2
1.5
—
—
—
0
0
21
200
1.05
0.03
1.6
1.5
28598.07
18247.07
e6/l
0.29
14
139
20
210
0.95
0.03
1.9
1.7
—
—
—
0
0
14
131
1.07
0.03
2.1
1.6
—
—
—
0
0
15
159
0.94
0.03
1.1
1.2
—
—
—
0
0
32
311
1.03
0.02
2.1
2.9
—
—
—
0
0
21
218
0.96
0.02
1.5
1.6
0.28
0.33
mg/l
—
7
101
16
153
1.05
0.01
1.6
1.6
—
—
—
0
0
97
979
0.99
0.01
1.3
1.3
20.62
35.92
iu/ml
1.61
26
303
21
216
0.97
0.00
2.0
1.7
—
—
—
0
0
29
284
1.02
0.00
3.4
3.8
4.56
2.81
ratio
0.21
15
167
21
215
0.98
0.00
1.4
1.3
—
—
—
0
0
17
167
1.02
0.00
1.6
1.6
—
—
—
0
0
28
277
1.01
0.00
2.8
3.2
26.55
25.10
mmol/l
0.96
28
271
22
222
0.99
0.00
1.4
1.7
—
—
—
0
0
13
129
1.01
0.00
1.1
1.3
—
287.14
—
0
14
14
139
1.01
0.00
1.1
1.7
39.00
44.35
nmol/l
0.38
14
127
561
5609
1.00
0.00
5.5
5.9
6.01
6.10
mmol/l
1.24
506
5061
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
55
0.91
-0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
67
0.89
-0.00
1.3
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
96.75
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
0.20
—
0
7
0
7
0.00
-0.00
0.0
2.7
—
33.71
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
7.8
—
—
—
0
0
6
63
0.95
-0.00
1.3
1.1
—
1.34
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
8
80
1.00
-0.00
1.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
6.0
—
—
—
0
0
6
66
0.91
-0.00
2.2
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
25.30
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
8.02
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint G6_BASDEGENOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_BASDEGENOTH | 5.541 [4.56, 6.72] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.285 |
During the follow-up period (1.1.1998 — 31.12.2019), 710 out of 1242 females with G6_BASDEGENOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_BASDEGENOTH | 4.925 [3.86, 6.29] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 960 out of 1580 males with G6_BASDEGENOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_BASDEGENOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.511% | 0.88% |
| 5 | 3.368% | 5.096% |
| 10 | 8.029% | 12.307% |
| 15 | 14.69% | 22.676% |
| 20 | 24.56% | 35.996% |
Relationships between endpoints
↥Index endpoint: G6_BASDEGENOTH – Other degenerative diseases of the basal ganglia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data